Original Research
Published on 22 Nov 2024
Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1492680
- Frontiers in Hematology
- Blood Cancer
- Articles
Type at least 3 characters
47 articles
Articles
Case Report
Accepted on 19 Nov 2024
Ruxolitinib and Peg-Interferon in Chronic neutrophilic leukemia due to CSF3R germline pathogenic variant: a case report
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1508463
Correction
Accepted on 18 Nov 2024
Refractory human cytomegalovirus infection without evidence of genetic resistance in the UL-54 and UL-97 genes in a pediatric hematopoietic stem cell transplant recipient: a case report
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1526535
Original Research
Accepted on 15 Nov 2024
Prevalence of Measurable Residual Disease (MRD) in Patients with refractory/relapsed Multiple Myeloma who Reached Complete Response: A Cross-sectional Multicentric Study
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1480120
Case Report
Published on 13 Nov 2024
Case report: VEXAS syndrome and literature review
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1480436
- 140 views
Mini Review
Accepted on 05 Nov 2024
Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1483322
Case Report
Accepted on 31 Oct 2024
A Rare Case of CNS-CLL Mimicking Demyelinating Disease: Multidisciplinary Approaches for Accurate Diagnosis
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1496758
Review
Published on 29 Oct 2024
Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1463410
- 335 views
Perspective
Published on 18 Oct 2024
The CHIP-clinic as the catalyst of preventive medicine
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1459154
- 368 views
Review
Published on 07 Oct 2024
Clonal evolution: a landmark of MPN evolution
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1473920
- 579 views
Original Research
Published on 11 Sep 2024
Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1438233
- 381 views
Study Protocol
Accepted on 20 Aug 2024
Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1436845
- 119 views
Editorial
Published on 14 Aug 2024
Editorial: Glycobiology in hematology: a promising avenue for cancer diagnostics and therapeutics
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1465473
- 509 views
Community Case Study
Published on 25 Jul 2024
Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1441070
- 494 views
Mini Review
Published on 22 Jul 2024
Targeting the bone marrow niche, moving towards leukemia eradication
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1429916
- 751 views
Review
Published on 12 Jul 2024
Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1419323
- 1,492 views